SAN CARLOS, Calif., May 25, 2017 /PRNewswire/ -- Rosa & Co., LLC is proud to welcome Matt Marano as the company's Senior Vice President of Business Development. Mr. Marano will be responsible for leading the continued expansion of the company's worldwide PhysioPD™ commercial strategy.
Mr. Marano joins the team from SolveBio (New York, NY) where he served as Senior Vice President of Commercial Development. During his tenure at SolveBio, he directed all sales and business development efforts, specifically focusing on VP- and C-level executives within the Life Sciences industry. Prior to SolveBio, Mr. Marano was Vice President of Sales and Business Development at Gen9 (acquired by Ginkgo Bioworks), a leading next-generation gene synthesis provider, where he successfully led the organization's commercial expansion in the United States, Europe, the Middle East and Africa.
Mr. Marano comes to Rosa with over 30 years' experience in the Life Sciences industry, both as a researcher and a commercial development professional, and has created and expanded the global commercial presence for many industry-leading life sciences firms, including Archimedes (acquired by Evidera), BioTrove's RapidFire business unit (now part of Agilent Technologies), Ardais Corporation, and Molecular Dynamics.
Mr. Marano holds a B.S. in Biology from Providence College, and completed graduate-level coursework in Molecular Biology at Providence College and Harvard University Extension School.
"I am thrilled to be joining the world-class team at Rosa & Co. I've focused much of my career on expanding the commercial presence of some of the Life Science industry's most impactful companies, and Rosa is truly the world leader in Quantitative Systems Pharmacology solutions for the Life Sciences industry," said Matt Marano about his appointment.
"We are fortunate that an executive of Matt's stature has joined our team. Together we can further expand our ability to offer PhysioPD Research to clients world-wide," said Founder, Chairman, & CEO Ron Beaver, PhD.
Rosa & Co was established in 2002 and has an extensive track record partnering with pharma and biopharma clients to reduce risk, optimize the efficient use of program resources, and prioritize candidate targets. PhysioPD Research, Rosa's quantitative systems pharmacology (QSP) approach, is an established scientific process that translates biology into customized computer models of physiology, disease, and drug effects.
Rosa works with client research teams to complement their work and develop a coherent model of the disease of interest. The resulting PhysioPD Research Platform incorporates the joint project team's scientific interpretation of existing data and their most relevant hypotheses to address biological uncertainties.
Rosa's PhysioPD Platforms help optimize the evaluation of novel targets and compounds, test the effects of new combination therapies, guide study and trial designs, and inform competitive differentiation. Rosa is unique in its breadth and depth of disease area experience—metabolic, cardiovascular, and inflammatory diseases; oncology and immuno-oncology; immune dysfunctions; central nervous system disorders; dermatology; and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com.
Patrick van der Valk
SOURCE Rosa & Co.